An interventional study of Use of AuryzoN™ EAR 2.0 device and Hand carving in Microtia, Congenital, Microtia and Microtia-Anotia, sponsored by Nemours Children's Clinic. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Congenital Microtia with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Congenital Microtia · United States.
Among the 11 studies in Congenital Microtia with a site in United States, this one is one of 2 that started in 2025, is one of 4 with no phase, and was the 11th registered.
33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.
Browse Congenital Microtia studies →3 of the 11 studies in Congenital Microtia with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18–89
Columbia University · Sites in United States, Brazil, Guatemala and 3 more countries
Ages 3–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Congenital Microtia studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 5 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 30 is below the median of 34 across 23 interventional studies indexed under Congenital Microtia.
Median enrollment 3 across the 8 interventional studies, 935 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 9 most frequent:
Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Nemours Children's Clinic has 1 study filed under Congenital Microtia — fewer than ten, so there is no comparison to draw.
1 of the studies in Congenital Microtia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05288790Vanderbilt University Medical CenterMicrobiome Metabolites and Alcohol in HIV to Reduce CVD RCT | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Congenital Microtia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to improve surgical outcomes for children and young adults with ear differences severe secondary to congenital conditions (like microtia, a condition where the ear is underdeveloped), trauma (such as dog bites), or surgical resections secondary to skin cancer. The investigators have developed a novel medical device to shape cartilage into pre-determined shapes that, once assembled, assists the surgeon in creating an anatomically accurate cartilaginous ear framework, reduce surgery time, and minimize wire need. Other factors that might affect the quality of surgical outcomes will be examined in clinical trial participants.
Cartilage-based ear reconstruction addresses congenital anomalies, such as microtia, as well as deformities due to trauma or oncologic resection by replacing like with like tissue. Current technique involves the use of the autologous cartilage as the gold standard and involves harvesting patient's own rib cartilage and carving them into different ear subunits, which are then assembled with numerous steel wires. Challenges of this technique include high operator-dependency due to extensive carving, inconsistent outcomes, prolonged anesthesia, and need for wire or suture fixation, leading to wire extrusion, cartilage resorption, and overall high cost. The previously published prototype device utilized specialized blades to standardize this process. Given the complexity of auricular reconstruction and the suboptimal outcomes by most plastic surgeons globally, there is a pressing need for a standardized, enhanced and accessible method for an accurate ear framework.
If successful, this project has the potential to improve plastic surgeons' technical proficiency in producing anatomically accurate auricular frameworks. Achieving these aims could substantially advance reconstructive clinical techniques in clinical practice and broaden access to satisfactory ear reconstruction beyond the limited number of highly specialized centers. Furthermore, the novel blade design has the potential to reduce the need for wire suturing, while also reducing overall framework production time, anesthesia duration, and costs.
Comparing hand-carved and blade-cut techniques for cadaveric cartilage, the study will enhance understanding of potential differences in resorption rate between these methods. This study aims to: 1. Promote framework production through precise bladecutting, facilitating the construction of cartilaginous ear frameworks while improving outcomes and reducing operative time and costs; 2. Standardize framework production independently of operator skill. 3. Reduce the number of wires required for construct fixation, further contributing to decreased operative time and cost; 4. Minimize the risk of wire extrusion by limiting wires usage during framework production through the novel blade design. 5. Compare differences in framework appearance, stability, time to production, operative time, intraoperative morbidity, and construct resorption within the first year postoperatively when using cadaveric cartilage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the AuryzoN™ EAR 2.0 arm will receive ear reconstruction surgery using the AuryzoN™ EAR 2.0 device
Procedure: Use of AuryzoN™ EAR 2.0 device
Participants in this arm will receive ear reconstruction surgery using the hand carved technique
Procedure: Hand carving
AuryzoN™ EAR 2.0 is an investigational non-significant risk device developed to improve cartilage construct shape and stability prior to use in ear reconstructive surgery.
Standard hand carving using standard surgical blades will be performed in this intervention arm of the study.
Evaluate the results of patient and parent satisfaction with the constructed ear's shape and appearance and compare the results between the hand-carved cohort and the AuryzoN™ EAR 2.0 cohort using a four-question survey.
Parents and patients (over age 12) will complete a four-question survey asking how much they like: the shape of the new ear, how the new ear looks, how natural the new ear looks, and the new ear overall. Participants will respond to each question with a rating from 1-5, with 1 being "do not like it at all" and 5 being "like it very much". Investigators will compare the responses from the hand-carved cohort and the AuryzoN™ EAR 2.0 cohort to determine which has more favorable outcomes.
Time frame: From the beginning of the study to the end at 5 years
Evaluating reduction in operative time between the two techniques.
Compare changes in operative time between participants enrolled in the AuryzoN™ EAR 2.0 arm and the traditional hand-carving arm.
Time frame: From the beginning of the study to the end at 5 years
Evaluating reduction in assembly time between the two techniques.
Compare the assembly time of cartilage into the ear construct between the AuryzoN™ EAR 2.0 arm and the hand-carving technique.
Time frame: From the beginning of the study to the end at 5 years
Evaluating reduction in wire usage between the two techniques
Compare the amount of wire required for assembly of the ear construct between the Auryzon™ EAR 2.0 arm and the hand-carving technique.
Time frame: From the beginning of the study to the end at 5 years
Evaluation of cartilage stability
Assess cartilage framework stability over 12 months post-surgically using photography, measurements, 3D imaging, and histopathological analysis.
Time frame: From the beginning of the study to the end at 5 years
Evaluation of resorption rates
Assess resorption rates over 12 months post-surgically using photography, measurements, 3D imaging and histopathological analysis.
Time frame: From the beginning of the study to the end at 5 years
Conduct histopathological analysis assessing outcomes of banked allogeneic cartilage between stage 1 and stage 2 surgeries
Cartilage will be banked in participants' groin or supraclavicular region during the six months between stage 1 and stage 2 ear reconstruction surgeries. Investigators will conduct histopathological analysis to assess the quality of the banked cartilage when it is recovered for use in the stage 2 surgery. This pathological analysis of the banked cartilage will be performed by using Hematoxylin \& Eosin (H\&E) staining and evaluating chondrocytes and extracellular matrix for signs of inflammatory response or rejection.
Time frame: From the beginning of the study to the end at 5 years
Assessing any changes to the dimensions of the banked cartilage when it is retrieved for stage 2 reconstruction surgery.
Surgeons will measure the dimensions of the cartilage before banking at the end of the stage 1 surgery and after retrieving the banked cartilage during the stage 2 surgery. Investigators will compare the dimensions of the cartilage before and after banking to determine whether there are any signing or warping or resorption
Time frame: From the beginning of the study to the end at 5 years
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.